Stock Analysis
Gilead Sciences, Inc. (GILD) Stock Analysis
Gilead Sciences, Inc. (GILD) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Gilead Sciences, Inc. (GILD) currently has an AIQ Score of 45/100, indicating a neutral setup. Momentum is the strongest factor at 71/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
GILD at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $153.57 |
| AIQ Score | 45/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $186.14B |
| P/E Ratio (TTM) | -57.66 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$8.45 |
| Revenue (quarter ended 2026-06-30) | $7.8B |
| Dividend Yield (TTM) | 2.15% |
| Beta | 0.34 |
| Volume | 6.21M |
| 52-week range | $114.02-$160.51 |
| RSI 14 | 59.04 |
| 50-Day SMA | $148.06 |
| 200-Day SMA | $138.53 |
| Analyst Price Target | $149.12 |
| Next Earnings | Oct 29, 2026 |
GILDGilead Sciences, Inc.
Healthcare / Drug Manufacturers - General
Low Priority
Relative Laggard
Latest quote
- Momentum71
- Value37
- Quality30
- Risk resilience45
- Sentiment71
GILD Stock Analysis Summary
Gilead Sciences, Inc. (GILD) currently has an AIQ Score of 45/100, indicating a neutral setup. Momentum is the strongest factor at 71/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, GILD has AIQ Score of 45/100 with Momentum base of 71/100 and fading Quality at 30/100. Wait for component alignment before adding exposure.
Momentum (71/100) leads while Quality (30/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.88% stock move · GILD classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is GILD Bullish or Bearish Right Now?
GILD currently has a neutral overall setup. Momentum is the strongest factor at 71/100, while Quality is weakest at 30/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 71/100.
- - Price is +3.72% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (33 vs 5).
- - Value is the current constraint at 37/100.
- - Analyst target implies -2.90% downside from the latest quote.
Current Consensus
GILD's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 7 neutral, and 5 sell votes. GILD's 14-day RSI is 59.04, which places the stock in a constructive momentum range. GILD's beta is 0.34, indicating lower market sensitivity than the broad market.
What Changed in GILD?
The largest recent change in GILD is Momentum moving up by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the GILD Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
GILD Decision Framework
Public evidence layers, setup checks, and risk context for Gilead Sciences, Inc..
Gilead Sciences, Inc. (GILD) Stock Analysis
Gilead Sciences, Inc. has an AIQ Score of 45/100 in a Neutral regime. Momentum is strongest at 71/100. Beta is 0.33, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | GILD is in a Neutral AIQ regime with score 45/100. |
| Signal Conflict | The primary conflict is that momentum leads at 71/100 while quality lags at 30/100. |
| Factor Evidence | Momentum 71/100 · Value 37/100 · Quality 30/100 · Risk 45/100 · Sentiment 71/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 71/100.
Momentum is 71/100 and RSI (14) is 59.0.
GILD is in a Neutral regime at 45/100.
Risk factor is 45/100 with beta 0.33 and annual volatility 26.86%.
Current conflict: momentum leads at 71/100 while quality lags at 30/100.
GILD Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
GILD Fundamentals
GILD valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
GILD Technical Analysis
GILD technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
GILD Stock Catalysts
Track GILD earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
GILD Dividend Analysis
GILD dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
GILD Financial Data
GILD revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
GILD Risk Analysis
GILD volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
GILD Stock News
GILD stock news, market tone, recent headlines, and catalyst context.
GILD vs Large Cap Pharma Peers
Current peer cohort: GILD · GSK · HLN · INCY · JNJ. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| GILD Current stock | 45/100 | 37/100 | 71/100 | 45/100 | 0.81 | 26.86% | Current |
| GSK GSK | 67/100 | 67/100 | 72/100 | 49/100 | 0.46 | 26.66% | GILD vs GSK |
| HLN Haleon | 62/100 | 56/100 | 79/100 | 48/100 | 0.22 | 23.24% | GILD vs HLN |
| INCY Incyte | 64/100 | 52/100 | 42/100 | 73/100 | 0.87 | 33.52% | GILD vs INCY |
| JNJ Johnson & Johnson | 52/100 | 39/100 | 48/100 | 48/100 | 1.31 | 20.43% | GILD vs JNJ |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 22, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching GILD
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for GILD
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
GILD Stock FAQ
What is GILD stock price today?
Gilead Sciences, Inc.'s current stock price is $153.57. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is GILD bullish or bearish right now?
GILD's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is GILD's market cap?
GILD's market cap is $186.14B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is GILD's current P/E ratio?
GILD's current P/E ratio is -57.66 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is GILD's RSI?
GILD's 14-day RSI is 59.04 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is GILD above its 50-day and 200-day moving averages?
GILD is 3.72% from its 50-day SMA and 10.86% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is GILD's next earnings date?
GILD's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does GILD pay a dividend?
GILD's dividend yield is 2.15% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.